- Home
- AVIR vs NMRA Comparison
AVIR vs NMRA Comparison
Compare AVIR & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- NMRA
- Stock Information
- Founded
- AVIR 2012
- NMRA 2019
- Country
- AVIR United States
- NMRA United States
- Employees
- AVIR N/A
- NMRA N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- NMRA
- Sector
- AVIR Health Care
- NMRA
- Exchange
- AVIR Nasdaq
- NMRA Nasdaq
- Market Cap
- AVIR 273.0M
- NMRA 234.5M
- IPO Year
- AVIR 2020
- NMRA 2023
- Fundamental
- Price
- AVIR $3.90
- NMRA $2.35
- Analyst Decision
- AVIR Hold
- NMRA Buy
- Analyst Count
- AVIR 1
- NMRA 8
- Target Price
- AVIR $6.00
- NMRA $7.14
- AVG Volume (30 Days)
- AVIR 426.9K
- NMRA 2.6M
- Earning Date
- AVIR 08-06-2025
- NMRA 08-06-2025
- Dividend Yield
- AVIR N/A
- NMRA N/A
- EPS Growth
- AVIR N/A
- NMRA N/A
- EPS
- AVIR N/A
- NMRA N/A
- Revenue
- AVIR N/A
- NMRA N/A
- Revenue This Year
- AVIR N/A
- NMRA N/A
- Revenue Next Year
- AVIR N/A
- NMRA N/A
- P/E Ratio
- AVIR N/A
- NMRA N/A
- Revenue Growth
- AVIR N/A
- NMRA N/A
- 52 Week Low
- AVIR $2.46
- NMRA $0.61
- 52 Week High
- AVIR $4.15
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- AVIR 67.66
- NMRA 85.38
- Support Level
- AVIR $3.36
- NMRA $1.70
- Resistance Level
- AVIR $3.53
- NMRA $2.17
- Average True Range (ATR)
- AVIR 0.15
- NMRA 0.30
- MACD
- AVIR -0.00
- NMRA 0.11
- Stochastic Oscillator
- AVIR 97.24
- NMRA 74.95
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.